Abstract
SARS-CoV-2, the causative agent of COVID-19, was declared a pandemic on March 11, 2020, and due to its high morbidity and mortality rates, it became a global health priority. Cuba developed its vaccines (SOBERANA 01, 02, and Plus), and as part of an intervention study launched in 2021 among healthcare workers, a booster dose was administered in November of that year. This study aimed to evaluate the humoral immune response after the SOBERANA 01 booster in workers at the Pedro Kourí Institute of Tropical Medicine (IPK) and to analyze its association with sociodemographic and clinical-epidemiological variables. A total of 418 whole blood and serum samples were collected one month after the booster, and anti-SARS- CoV-2 antibodies were assessed using a lateral flow immunochromatographic assay and the UMELISA SARS-CoV-2 IgG technique. The rapid assay detected IgG in 95.7% of samples and marginal IgM positivity (0.23%), while UMELISA confirmed IgG in 99.5% of cases. No significant differences were observed according to sociodemographic or clinical characteristics, although a positive association was found between prior COVID-19 infection and rapid test positivity. These findings demonstrate that SOBERANA 01 induces a strong humoral response in healthcare workers, supporting its use in high-risk populations and confirming that Cuban-developed vaccines provide immune protection comparable to internationally recognized platforms.

This publication has 23 references indexed in Scilit: